Publications by authors named "Laia Bardolet"
Improvement in quality of life in patients treated with lebrikizumab monotherapy is mediated by improvement in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis.
Gil Yosipovitch Marjolein de Bruin-Weller Marni Wiseman Jesper Elberling Jan Gutermuth Laia Bardolet
Clin Exp Dermatol
December 2024
Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody which binds IL-13, a dominant cytokine implicated in AD. This study includes data from two Phase 3 randomized controlled trials assessing the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967).
View Article and Find Full Text PDFArticle Synopsis
- - Lebrikizumab significantly improved skin clearance and patient-reported outcomes in moderate-to-severe atopic dermatitis over 52 weeks, with particular benefits seen in itch and sleep loss relief as measured by the Patient-Oriented Eczema Measure (POEM).
- - In clinical trials (ADvocate1 and ADvocate2), patients who responded well to lebrikizumab at 16 weeks were further analyzed; over time, an increasing percentage reported minimal itch and sleep disturbances by week 52.
- - Results showed that by week 52, a notable percentage of patients experienced almost complete relief from itch (44.6% to 48.0% reported minimal itch) and improved sleep quality (78.4